Life sciences licensing deals in the first quarter of 2018: updates and trends.

Drugs Today (Barc)

Clarivate Analytics, Barcelona, Spain.

Published: June 2018

During the first quarter of 2018, Cortellis Competitive Intelligence registered 879 new deals (excluding mergers and acquisitions) with a total disclosed deal value of approximately USD 35.2 billion as part of its ongoing coverage of licensing activity in the life sciences sector. This compares to 1,203 and USD 26.2 bil-lion in the fourth quarter of 2017, and 1,158 and USD 31.8 billion in the first quarter of 2017. This meant a significant increase in the total disclosed deal value compared to these two previous periods (+34% and +10.7%, respectively), and included the USD 5.8 billion pact between Merck and Co. and Eisai which became the highest-value deal in the last 4-year opening quarters. However, during the first quarter of 2018 there was not a high number of signed agreements versus the fourth quarter of 2017 and the first quarter of 2017 (-27% and -24%, respectively), reaching a number similar to that in the first quarter of 2014 with a total of 931 agreements covered.

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2018.54.6.2856494DOI Listing

Publication Analysis

Top Keywords

quarter 2017
16
quarter 2018
12
life sciences
8
quarter
8
total disclosed
8
disclosed deal
8
fourth quarter
8
sciences licensing
4
licensing deals
4
deals quarter
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!